Skip to main content
PMC home page
Cell Death Discovery logoLink to Cell Death Discovery
. 2020 Mar 17;6:14. doi: 10.1038/s41420-020-0249-4

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer

Silvia von Karstedt 1,2,3,✉, Henning Walczak 2,4,5,✉
PMCID: PMC7078304  PMID: 32194994

Abstract

Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pancreatic ductal adenocarcinomas (PDAC). Importantly, survival of patients with KRAS-mutated PDAC and NSCLC has not significantly improved since the 1970s highlighting an urgent need to re-examine how oncogenic KRAS influences cell death signaling outputs. Interestingly, cancers expressing oncogenic KRAS manage to escape antitumor immunity via upregulation of programmed cell death 1 ligand 1 (PD-L1). Recently, the development of next-generation KRASG12C-selective inhibitors has shown therapeutic efficacy by triggering antitumor immunity. Yet, clinical trials testing immune checkpoint blockade in KRAS-mutated cancers have yielded disappointing results suggesting other, additional means endow these tumors with the capacity to escape immune recognition. Intriguingly, oncogenic KRAS reprograms regulated cell death pathways triggered by death receptors of the tumor necrosis factor (TNF) receptor superfamily. Perverting the course of their intended function, KRAS-mutated cancers use endogenous TNF-related apoptosis-inducing ligand (TRAIL) and its receptor(s) to promote tumor growth and metastases. Yet, endogenous TRAIL–TRAIL-receptor signaling can be therapeutically targeted and, excitingly, this may not only counteract oncogenic KRAS-driven cancer cell migration, invasion, and metastasis, but also the immunosuppressive reprogramming of the tumor microenvironment it causes. Here, we provide a concise summary of the current literature on oncogenic KRAS-mediated reprogramming of cell death signaling and antitumor immunity with the aim to open novel perspectives on combinatorial treatment strategies involving death receptor targeting.

Subject terms: Cell death, Cell biology

Facts

  • KRAS is the most frequently mutated proto-oncogene in human cancers.

  • KRAS-mutated cancers show poor checkpoint blockade response.

  • TNF superfamily ligand signaling is re-programmed to mediate migration, invasion, and metastasis in KRAS-mutated cancer.

Open questions

  • Can antagonistic targeting of TNF superfamily ligand signaling impact KRAS-driven cancer?

  • How does targeting of TNF superfamily ligand signaling influence the tumor immune environment?

  • Could targeting of TNF superfamily ligand signaling serve as an alternative immunotherapeutic approach for KRAS-mutated cancers?

KRAS-mutated cancers: cancers with unmet needs

Survival rates for most KRAS-mutated cancers such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) have not significantly improved since the 1970s. This dire situation is, in part, caused by the fact that KRAS-mutant cancers including PDAC are commonly only diagnosed at an advanced stage due to the absence of early symptoms. Whereas many KRAS effector pathways have been targeted using small molecule inhibitors against kinases activated downstream of KRAS1, their clinical application has raised concern over toxicity and even paradoxical effects promoting the disease through transactivation of wild-type (WT) v-raf murine sarcoma viral oncogene homolog B1(BRAF)2. Other potentially KRAS-mutant-selective therapeutic targets have emerged from synthetic lethality screens comparing effects on KRAS-mutated vs. KRAS WT cell lines3–7. However, the fact that activating point mutations uniquely occur in tumor cells has fueled efforts to develop small molecule inhibitors designed to selectively target these point mutant variants. As such, inhibitors that selectively bind and inactivate KRASG12C 8,9 have been developed showing promising results in first human trials10. Whilst hopes are high that this may provide a silver bullet against KRASG12C-mutated cancers, the fate of inhibitors of oncogenic BRAFV600E has taught us to be careful with such hopes. Most importantly, however, cancers driven by all other forms of point-mutated KRAS including KRASG12D, the most prevalent KRAS point mutation across all human cancers11, remain difficult to treat. Apart from these drug discovery-driven approaches, cell biological research has unearthed several important concepts highlighting mechanisms of how oncogenic KRAS manipulates antitumor immunity and physiological cell death signaling. These two concepts, which turn out to be a lot more closely interlinked at the level of immune cell–tumor cell encounters than previously thought, will be discussed in this review.

Patients with KRAS-mutated PDAC do not benefit from immune checkpoint blockade

Undeniably, the second decade of the third millennium has been the decade in which the inhibition of so-called immune checkpoints which serve to prevent autoimmunity12 has come of age in cancer therapy. The two immune checkpoint receptor–ligand systems whose inhibition has proven to be successful in the cancer clinic are the cytotoxic T lymphocyte-associated protein 4 (CTLA4)–B7-1/B7-213 and the programmed cell death protein-1 (PD-1)–programmed cell death 1 ligand 1 (PD-L1) systems14. Indeed, immune checkpoint blockade (ICB) has become a gamechanger in the therapy of certain cancers, especially advanced melanoma, with unprecedented response rates15–18. Interestingly, expression of oncogenic RAS has been shown to upregulate PD-L1 via stabilization of its mRNA19, suggesting this as a possible means by which KRAS-mutated cancers may escape immunosurveillance. However, in PDAC, ICB so far failed to provide clinical benefit20–22 (summarized in Table 1, also reviewed in23,24). This may, in part, be caused by the fact that cancers require a high tumor mutational burden (TMB) to achieve therapeutic efficacy via checkpoint blockade25,26. PDAC, the cancer with the highest incidence of KRAS mutations, however, does not present with very high TMB27. In addition, tumors that initially respond to ICB due to high TMB may acquire resistance by inactivation of the IFN-γ pathway28,29. Intriguingly, however, an inhibitor which selectively targets oncogenic KRASG12C, AMG510 was recently found to enable effective antitumor immunity10. Interestingly, this immune response was sufficient to also attack KRASG12D-expressing tumors in trans demonstrating that antitumor immunity is prevented by oncogenic KRAS, but can be re-instated through its inhibition. Together with the fact that PDAC patients poorly respond to ICB, these results imply that an alternative mechanism functionally similar to, but molecularly distinct from, conventional immune checkpoints is responsible for oncogenic KRAS-driven reprogramming of the tumor immune microenvironment (TIME) and, consequently, for immune evasion of KRAS-mutated cancers. Another possibility is that, besides conventional immune checkpoints, this currently elusive immune checkpoint provides an additional layer of protection preventing recognition and destruction by the immune system.

Table 1.

Selection of published and ongoing clinical trials testing immune checkpoint blockade (ICB) in pancreatic cancer.

Trial identifier Cancer types Treatment groups Response Reference
Completed PDAC, NSCLC, Melanoma, CRC, renal cancer, ovarian cancer, gastric cancer, breast cancer BMS-936559 (anti-PD-L1) 0% (PDAC) 21
Completed Previously treated PDAC Ipilimumab 0%, 1 delayed PR 22
Completed Previously treated PDAC Durvalumab (D; anti-PD-L1) vs. Durvalumab + Tremelimumab (T; anti-CTLA-4) 0% 3% (D/T) PR 20
NCT03871959 Advanced/meta-static PDAC/CRC Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + Debio1143 (Db; SMAC mimetic) pending N/A
NCT03634332 Previously treated PDAC Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + PEGPH20 (hyaluronidase) pending N/A
NCT03767582 Previously treated PDAC Nivolumab (anti-PD-1) combination with BMS-813160 (CCR2/CCR5 Dual Antagonist) and GVAX pending N/A
NCT02777710 Advanced/meta-static PDAC/CRC Durvalumab (D; anti-PD-L1) vs. Durvalumab + Pexidartinib (P; kinase inhibitor against colony-stimulating factor-1 receptor; CSF1R) pending N/A
NCT03727880 Resectable PDAC Pembrolizumab (Pe; anti-PD-1) vs. Pembrolizumab + Defactinib (De; inhibitor against focal adhesion kinase, FAK) pending N/A
Open in a new tab

PR partial response, NSCLC non-small cell lung cancer, CRC colorectal cancer.

The TNF superfamily member TRAIL and its receptors

Tumor necrosis factor is the founding member of the TNF superfamily (TNF-SF) of cytokines. Members of the TNF-SF are synthesized as type II transmembrane proteins. They are frequently expressed by activated immune cells but can also be cleaved from their surface and can then act as soluble cytokines30. Tumors are constitutively exposed to the functional consequences of signaling induced by various members of the TNF-SF, produced by diverse immune cells in the TIME, as part of the immune cell-mediated antitumor attack. Members of the TNF-SF bind to specific receptors that form part of a corresponding protein family, the TNF-receptor (TNFR)-SF. Members of this family are characterized by the presence of up to six repeats of a characteristic cysteine-rich domain within their extracellular portion. Six members of the TNFR-SF contain a so-called intracellular death domain (DD), which is required for cell death induction. These receptors are therefore also referred to as death receptors. The most intensively studied receptors of this type are TNF-receptor 1 (TNF-R1), CD95 (Fas/APO-1), and the two TRAIL death receptors, TRAIL-receptor 1 and 2 (TRAIL-R1 and TRAIL-R2)31.

Within this protein family, TRAIL32 received a high level of interest due to its capacity to selectively kill tumor cells, importantly without killing any essential normal cell type33,34. TRAIL has been shown to bind five different cellular receptors, which can be subdivided into the ones that contain a DD, TRAIL-R1 (DR4), and TRAIL-R2 (DR5), and those that do not, TRAIL-R3, TRAIL-R4, and osteoprotegerin (OPG) (reviewed in35–37). OPG is a soluble regulatory receptor for RANKL but has been shown to also bind TRAIL. Mice only express one DD-containing receptor for TRAIL (mTRAIL-R/MK) which is equally homologous to human TRAIL-R1 and TRAIL-R2. Moreover, two additional mouse receptors, mDcTRAIL-R1 and mDcTRAIL-R2, have been described which lack an intracellular DD. All of the alternative human and murine TRAIL-Rs have been suggested to function as ligand “decoys”, competing for TRAIL binding to the cell death-inducing receptors, a theoretical concept which has been rather difficult to validate under non-overexpression conditions. Recently, the membrane-proximal domain (MPD) within human TRAIL-R2, an amino acid sequence which is shared with mTRAIL-R, was identified to be required for Rac1 activation and migration in KRAS-driven cancers38. Of note, the MPD of TRAIL-R2 shares a lower degree of conservation with that of TRAIL-R1 than with the MPD of CD95, a death receptor which has been shown to activate Rac1 in neurons39.

TRAIL-induced signaling pathways: a brief recapitulation of the corner stones

FADD/Caspase 8-dependent apoptotic TRAIL signaling

Upon binding of TRAIL, TRAIL-R1 and TRAIL-R2 form homotrimeric, possibly also heterotrimeric receptor–ligand complexes that are assembled into large, higher-order complexes40,41. Receptor oligomerization allows for the recruitment of Fas-associated protein with a death domain (FADD) via its DD to the DD of TRAIL-R1 and/or TRAIL-R2. Making use of its death-effector domain (DED), FADD recruits the initiator caspases 8 and 10 via their respective DEDs. The resulting complex is referred to as the death-inducing signaling complex (DISC)42–44. Upon activation and cleavage, active caspases 8 and 10 are released from the DISC allowing for the cleavage of cytosolic substrates including effector caspases such as caspase 3. Finally, effector caspases cleave inhibitor of caspase-activated DNAse (iCAD) leading to the activation of caspase-activated DNAse (CAD), which is responsible for the hallmark DNA fragmentation observed during apoptosis45. In so-called type I cells, DISC formation is sufficient to induce extrinsic apoptosis in target cells. Yet in type II cells, DISC formation alone is insufficient for full activation of effector caspases due to the inhibitory effect exerted by the X-linked inhibitor of apoptosis protein (XIAP) 46. However, caspase 8 also cleaves Bid. Truncated Bid aids Bax- and Bak-mediated mitochondrial outer membrane permeabilization (MOMP)47. MOMP leads to the release of Smac/DIABLO into the cytosol, which antagonizes XIAP. In type II but not in type I cells, this part of the pathway is required for cell death induction, providing a molecular explanation for the type I–type II cell dichotomy. Another consequence of MOMP is the release of cytochrome C from mitochondria which, together with Apaf1 and the initiator caspase 9, forms the apoptosome, a multimeric caspase-activatory complex which is also capable of activating effector caspases48—essentially serving as an “intracellular DISC”.

RIPK1/RIPK3-dependent necroptotic TRAIL signaling

Apoptotic DISC components have been shown to actively suppress aberrant induction of necroptosis, a type of regulated or programmed necrosis49. This was first proven genetically by showing that embryonic lethality of deficiency in caspase 8 or FADD could be reversed by co-ablation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3)50,51 or RIPK152,53. Therefore, unlike apoptosis, necroptosis is not mediated but suppressed by caspase activity. Instead, necroptosis is executed by the kinase activity of RIPK1 and RIPK354. Whilst most studies on necroptosis have been in the context of TNF stimulation, CD95L and TRAIL can be necroptotic under certain conditions. Interestingly, the linear ubiquitin chain assembly complex (LUBAC) forms part of both, the TRAIL-R1/2-associated complex I and the cytoplasmic complex II55 of TRAIL signaling, limiting TRAIL-induced apoptosis and necroptosis56.

RIPK1-dependent pro-tumor TRAIL signaling

Signaling via TRAIL-R1, TRAIL-R2 and TRAIL-R4 can induce activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a master regulator of the immune response. In the context of TRAIL stimulation, NF-κB promotes migration and invasion57. Interestingly, RIPK1 presence in the native TRAIL DISC was shown to augment NF-κB activation when caspases are inhibited58. Moreover, TRAIL-induced NF-kB activation is increased by FADD presence59, caspase inhibition, and LUBAC activity56. Apart from a role for RIPK1 in the DISC as an activator of NF-κB, the formation of a secondary intracellular signaling complex has been proposed to activate NF-κB, mitogen-activated protein kinases (MAPKs), JNK, and p38 pathways55. In vitro, TRAIL can trigger migration in a RIPK1-, Schmidt-Ruppin A-2 viral oncogene homolog (Src)- and Signal transducer and activator of transcription 3 (STAT3)-dependent manner60. Lastly, RIPK1 has been reported to be required for TRAIL-induced NF-κB activation61, survival, and proliferation.

Oncogenic KRAS-mediated rewiring of TRAIL signaling

Activating point mutations in the small GTPase KRAS lead to its constitutive activation1. Thereby, cancers with KRAS mutations experience constitutively elevated signaling via KRAS effector pathways such as activation of the phosphatidylinositol 3 kinase (PI3) kinase pathway via direct interaction of KRAS with the catalytic PI3K subunit p110α62. Interestingly, p110α overexpression in melanocytes can protect cells from TRAIL-induced apoptosis63. Moreover, small molecule inhibition of PI3K was shown to sensitize to TRAIL-induced apoptosis through elevating Bid expression64. Yet, studies using small molecules inhibitors for PI3K without further target validation have to be taken with a note of caution as the kinase inhibitor PIK-75, thought to act through inhibition of p110α, sensitizes cancer cells to TRAIL-induced apoptosis by inhibiting CDK9, whereas specific inhibitors of p110α failed to exert this effect65.

Another major effector pathway activated by oncogenic KRAS is the MAPK-family member extracellular regulated kinase (ERK), which can also be activated by TRAIL66. Importantly, inactivation of ERK signaling as a consequence of cellular detachment can sensitize cancer cells to TRAIL-induced apoptosis67. Given these and other studies, it was expected that KRAS-mutated cells would be more resistant to TRAIL-induced apoptosis. Yet, it came as a surprise when oncogenic KRAS was found to not only render colorectal cancer cells resistant to TRAIL and CD95L, but to convert the respective ligand-induced signals into migration-activating ones68. Moreover, treatment with exogenous TRAIL promoted KRAS-mutated PDAC metastases69. Whilst these studies highlighted KRAS mutations as contraindication for TRAIL-R agonistic treatments, the function and reasons for high endogenous expression of TRAIL and TRAIL-Rs observed in these cancers remained unknown. Intriguingly, however, these findings proposed an intriguing hypothesis: cancers might profit from highly expressing TRAIL and TRAIL-Rs. Indeed, this hypothesis proved to be correct as endogenous tumor cell-expressed mTRAIL-R promoted KRAS-driven NSCLC and PDAC growth and metastasis by activating the small GTPase Rac1 in vivo38. Moreover, Rho-associated protein kinase (ROCK) inhibition by oncogenic KRAS was sufficient to enable endogenous TRAIL-R2-mediated migration also in KRAS wild-type cells38 (concept summarized in Fig. 1). The latter observation implies that this previously unrecognized mechanism may be more widely utilized, also in oncogenic contexts beyond cancer with mutated KRAS. Of note, c-Raf which can function as a KRAS effector upstream of ERK was shown to suppress ROCK, thereby regulating CD95-mediated cell death70. Hence, inhibition of the interactions of endogenous TRAIL–TRAIL-R2 and/or CD95L–CD95 may prove a viable therapeutic concept in oncogene-activated cancers with ROCK inhibition.

Fig. 1. KRAS-mediated rewiring of TRAIL signaling.

Fig. 1

Open in a new tab

Cancer cell-produced TRAIL can bin TRAIL-R2 leading to autocrine cell-autonomous stimulation of Rac1-dependent migration. This signal is independent of the death domain (DD) but requires the membrane-proximal domain (MPD) of TRAIL-R2. Rac1 activity is normally inhibited by ROCK. Upon oncogenic activation of KRAS, KRAS inhibits ROCK, thereby releasing Rac1 to be fully activated by TRAIL-R2.

Immune-modulatory activities of TRAIL–TRAIL-R interaction: an immune checkpoint for KRAS-mutated cancer?

The therapeutic effect of inhibition of TRAIL or CD95L may, however, extend beyond the reach of blocking their role in tumor biology. In this context, it appears particularly noteworthy that mice deficient for TRAIL-R71 or TRAIL are more susceptible to induction of autoimmune diabetes72 and arthritis73 suggesting a function for the TRAIL–TRAIL-R system in preventing autoimmunity. In line with this concept, TRAIL expression on T cells was shown to induce tolerance upon encounter with potentially immunogenic antigens in order to prevent aberrant immune responses74. Moreover, TRAIL upregulation on CD4+ Foxp3+ regulatory T cells (Tregs) was responsible for the elimination of T effector cells in a skin graft model and, thereby, for suppression of anti-graft immunity75. In addition, co-activation of TRAIL-Rs and the T-cell receptor has been shown to suppress T-cell activation76.

Intriguingly, many biological effects observed for endogenous TRAIL–TRAIL-R signaling are reminiscent of the effects observed for immune checkpoints preventing autoimmune disease12. In a similar manner to the PD-1–PD-L1 system, expression of TRAIL and its receptors is frequently upregulated in cancer38,77–79. Interestingly, in PDAC, a cancer in which conventional ICB failed to provide clinical benefit, high PD-L1 expression only correlates with shortened progression-free but not overall survival (Fig. 2a, b). Importantly, in the same PDAC patient cohort, high TRAIL expression does not correlate with progression-free but with shortened overall survival (Fig. 2c, d), suggesting that the inhibition of TRAIL may provide therapeutic benefit for PDAC patients. Endogenous TRAIL-R2 was shown to promote KRAS-driven cancer through cancer cell-autonomous Rac1 activation and non-cancer-cell-autonomous reprogramming of the TIME into one conducive of type 2 macrophage accumulation38,59. Thus, blocking the TRAIL–TRAIL-R2 interaction may be beneficial for patients with KRAS-mutated cancers by acting on three levels: (i) by blocking cell-autonomous Rac1 activation; (ii) through inhibiting the creation of a type 2 macrophage-conducive TIME; and (iii) by prolonging CD8 T-cell activation, allowing for an increased level of “auto-reactive” immunity functionally similar to, but, importantly, molecularly distinct from, conventional ICB (concepts summarized in Fig. 3).

Fig. 2. TRAIL expression is a superior marker of overall survival in PDAC.

Fig. 2

Open in a new tab

a, c The TCGA PDAC dataset (PAAD) was analyzed for overall survival split by median expression of PD-L1 (CD274, a) or TRAIL (TNFSF10, c). b, d Data as in a, c were analyzed for disease free survival. Kaplan-Meier survival plots are shown. The GEPIA analysis tool was used (http://gepia.cancer-pku.cn).

Fig. 3. Potential impact of TRAIL/TRAIL-R blockade on tumor cell intrinsic signaling and reprograming of the tumor immune microenvironment (TIME).

Fig. 3

Open in a new tab

Endogenous TRAIL/TRAIL-R signaling eliminates activated CD8 T cells and promotes Rac1 activation and M2-polarizing chemo-/cytokine induction in tumor cells. Blockade of TRAIL/TRAIL-R expression prolongs survival of activated CD8 T cells, allows for an M1 polarized TIME and abrogates tumor cell Rac1 activity.

Conclusions

Although the discovery of conventional ICB has revolutionized the therapy of several cancers, unfortunately PDAC, the cancer with the highest incidence of KRAS mutations, does not form part of this group. Reasons for this may partly lie in poor immunogenicity and poor perfusion. Yet, KRAS-mutated tumors appear to drive immune evasion via alternative means, in addition to manipulating PD-L1 expression. Interestingly, KRAS-mutated cancers often highly express TRAIL and TRAIL-Rs. Whereas KRAS-mutated tumors are more resistant to induction of apoptosis by ectopically added TRAIL, they engage the endogenous TRAIL–TRAIL-R system in disease progression. In addition, the survival of activated CD8 T cells is regulated via TRAIL–TRAIL-R. We conclude that inhibiting endogenous TRAIL in KRAS-mutated cancers may not only inhibit tumor growth, invasion, and metastasis, but also enhance adaptive immunity against these cancers. In keeping with the irony of PD-1, being originally named for its supposed function as an inducer of programmed death, the bona fide TRAIL–TRAIL-R and CD95L–CD95 death receptor–ligand systems may turn out to serve as alternative, possibly additional immune checkpoint systems whose inhibition may prove essential to extend the ICB concept beyond the conventional ICBs, importantly, also to KRAS-mutated cancer.

Acknowledgements

This review is dedicated to the memory of the wonderful human being, our friend Yoel Kloog, who always appreciated a “school of provocative thought” in science. S.v.K. is funded by a Max-Eder-Junior Research Group grant (701125509) by the German Cancer Aid, by the German Research Foundation (DFG) in the context of a project grant (432038712), SFB 1399 and SFB 1403, an eMed consortium grant (01ZX1901A) funded by the German state (BMBF) and a project grant (A06) funded by the center for molecular medicine (CMMC), Cologne, Germany. H.W. is supported by an Alexander von Humboldt Professorship Award, a Wellcome Trust Investigator Award (214342/Z/18/Z), a Cancer Research UK (CRUK) programme grant (A27323), a Medical Research Council UK Grant (MR/S00811X/1) and the German Research Foundation (DFG) in the context of SFB 1399 and SFB 1403.

Conflict of interest

S.v.K. and H.W. are named inventors on one (S.v.K.) and two (H.W.) patent applications, respectively, covering some of the therapeutic concepts discussed here. H. W. is founder and shareholder of Apogenix AG, a biopharmaceutical company which develops a biotherapeutic inhibitor of CD95L.

Footnotes

Edited by I. Amelio

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Silvia von Karstedt, Email: s.vonkarstedt@uni-koeln.de.

Henning Walczak, Email: h.walczak@uni-koeln.de.

References

  • 1.Downward J. Targeting RAS and PI3K in lung cancer. Nat. Med. 2008;14:1315–1316. doi: 10.1038/nm1208-1315. [DOI] [PubMed] [Google Scholar]
  • 2.Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–430. doi: 10.1038/nature08902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Singh A, Settleman J. Oncogenic K-ras ‘addiction’ and synthetic lethality. Cell Cycle. 2009;8:2676–2677. doi: 10.4161/cc.8.17.9336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Luo J, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137:835–848. doi: 10.1016/j.cell.2009.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112. doi: 10.1038/nature08460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kumar MS, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012;149:642–655. doi: 10.1016/j.cell.2012.02.059. [DOI] [PubMed] [Google Scholar]
  • 7.Dietlein F, et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant. Cancer Cell. 2015;162:146–159. doi: 10.1016/j.cell.2015.05.053. [DOI] [PubMed] [Google Scholar]
  • 8.Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551. doi: 10.1038/nature12796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Patricelli MP, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316–329. doi: 10.1158/2159-8290.CD-15-1105. [DOI] [PubMed] [Google Scholar]
  • 10.Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–223. doi: 10.1038/s41586-019-1694-1. [DOI] [PubMed] [Google Scholar]
  • 11.Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J. Cell. Sci. 2016;129:1287–1292. doi: 10.1242/jcs.182873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12:252–264. doi: 10.1038/nrc3239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736. doi: 10.1126/science.271.5256.1734. [DOI] [PubMed] [Google Scholar]
  • 14.Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 2005;6:280–286. doi: 10.1038/ni1165. [DOI] [PubMed] [Google Scholar]
  • 15.Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–723. doi: 10.1056/NEJMoa1003466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Margolin K, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–465. doi: 10.1016/S1470-2045(12)70090-6. [DOI] [PubMed] [Google Scholar]
  • 17.Ribas A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013;31:616–622. doi: 10.1200/JCO.2012.44.6112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015;372:320–330. doi: 10.1056/NEJMoa1412082. [DOI] [PubMed] [Google Scholar]
  • 19.Coelho MA, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083–1099.e6. doi: 10.1016/j.immuni.2017.11.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.O’Reilly EM, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1431. doi: 10.1001/jamaoncol.2019.1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;366:2455–2465. doi: 10.1056/NEJMoa1200694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Royal RE, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010;33:828–833. doi: 10.1097/CJI.0b013e3181eec14c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Johnson BA, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for increasing pancreatic tumor immunogenicity. Clin. Cancer Res. 2017;23:1656–1669. doi: 10.1158/1078-0432.CCR-16-2318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Henriksen A, Dyhl-Polk A, Chen I, Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 2019;78:17–30. doi: 10.1016/j.ctrv.2019.06.005. [DOI] [PubMed] [Google Scholar]
  • 25.Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014;371:2189–2199. doi: 10.1056/NEJMoa1406498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Van Allen EM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–211. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gao J, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397–404.e9. doi: 10.1016/j.cell.2016.08.069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in Melanoma. N. Engl. J. Med. 2016;375:819–829. doi: 10.1056/NEJMoa1604958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003;3:745–756. doi: 10.1038/nri1184. [DOI] [PubMed] [Google Scholar]
  • 31.Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501. doi: 10.1016/s0092-8674(01)00237-9. [DOI] [PubMed] [Google Scholar]
  • 32.Wiley SR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682. doi: 10.1016/1074-7613(95)90057-8. [DOI] [PubMed] [Google Scholar]
  • 33.Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999;5:157–163. doi: 10.1038/5517. [DOI] [PubMed] [Google Scholar]
  • 34.Ashkenazi A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999;104:155–162. doi: 10.1172/JCI6926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Karstedt von,S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat. Publ. Group. 2017;17:352–366. doi: 10.1038/nrc.2017.28. [DOI] [PubMed] [Google Scholar]
  • 36.Lemke J, Karstedt von,S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21:1350–1364. doi: 10.1038/cdd.2014.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J. Clin. Invest. 2015;125:487–489. doi: 10.1172/JCI80420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Karstedt von,S, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27:561–573. doi: 10.1016/j.ccell.2015.02.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ruan W, Lee CT, Desbarats J. A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell. 2008;19:3192–3202. doi: 10.1091/mbc.E08-02-0161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Valley CC, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J. Biol. Chem. 2012;287:21265–21278. doi: 10.1074/jbc.M111.306480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Graves JD, et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell. 2014;26:177–189. doi: 10.1016/j.ccr.2014.04.028. [DOI] [PubMed] [Google Scholar]
  • 42.Kischkel FC, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611–620. doi: 10.1016/s1074-7613(00)80212-5. [DOI] [PubMed] [Google Scholar]
  • 43.Kischkel FC, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 2001;276:46639–46646. doi: 10.1074/jbc.M105102200. [DOI] [PubMed] [Google Scholar]
  • 44.Sprick MR, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599–609. doi: 10.1016/s1074-7613(00)80211-3. [DOI] [PubMed] [Google Scholar]
  • 45.Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391:96–99. doi: 10.1038/34214. [DOI] [PubMed] [Google Scholar]
  • 46.Jost PJ, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460:1035–1039. doi: 10.1038/nature08229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Schug ZT, Gonzalvez F, Houtkooper RH, Vaz FM, Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 2011;18:538–548. doi: 10.1038/cdd.2010.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Pan G, O’Rourke K, Dixit VM. Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J. Biol. Chem. 1998;273:5841–5845. doi: 10.1074/jbc.273.10.5841. [DOI] [PubMed] [Google Scholar]
  • 49.Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517:311–320. doi: 10.1038/nature14191. [DOI] [PubMed] [Google Scholar]
  • 50.Kaiser WJ, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471:368–372. doi: 10.1038/nature09857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Oberst A, et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363–367. doi: 10.1038/nature09852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Dillon CP, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell. 2014;157:1189–1202. doi: 10.1016/j.cell.2014.04.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Zhang H, et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471:373–376. doi: 10.1038/nature09878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138:229–232. doi: 10.1016/j.cell.2009.07.006. [DOI] [PubMed] [Google Scholar]
  • 55.Varfolomeev E, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 2005;280:40599–40608. doi: 10.1074/jbc.M509560200. [DOI] [PubMed] [Google Scholar]
  • 56.Lafont E, et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 2017;36:1147–1166. doi: 10.15252/embj.201695699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006;290:G129–G136. doi: 10.1152/ajpgi.00242.2005. [DOI] [PubMed] [Google Scholar]
  • 58.Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 2001;276:34743–34752. doi: 10.1074/jbc.M105693200. [DOI] [PubMed] [Google Scholar]
  • 59.Hartwig T, et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol. Cell. 2017;65:730–742.e5. doi: 10.1016/j.molcel.2017.01.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Azijli K, et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J. Cell. Sci. 2012;125:4651–4661. doi: 10.1242/jcs.109587. [DOI] [PubMed] [Google Scholar]
  • 61.Lin Y, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 2000;20:6638–6645. doi: 10.1128/mcb.20.18.6638-6645.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Gupta S, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129:957–968. doi: 10.1016/j.cell.2007.03.051. [DOI] [PubMed] [Google Scholar]
  • 63.Larribere L, et al. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ. 2004;11:1084–1091. doi: 10.1038/sj.cdd.4401475. [DOI] [PubMed] [Google Scholar]
  • 64.Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene. 2010;29:5523–5536. doi: 10.1038/onc.2010.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Lemke J, et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 2014;21:491–502. doi: 10.1038/cdd.2013.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Belyanskaya LL, et al. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer. 2008;60:355–365. doi: 10.1016/j.lungcan.2007.11.005. [DOI] [PubMed] [Google Scholar]
  • 67.Grosse-Wilde A, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 2008;118:100–110. doi: 10.1172/JCI33061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Hoogwater FJH, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology. 2010;138:2357–2367. doi: 10.1053/j.gastro.2010.02.046. [DOI] [PubMed] [Google Scholar]
  • 69.Trauzold A, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25:7434–7439. doi: 10.1038/sj.onc.1209719. [DOI] [PubMed] [Google Scholar]
  • 70.Piazzolla D, Meissl K, Kucerova L, Rubiolo C, Baccarini M. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling. J. Cell Biol. 2005;171:1013–1022. doi: 10.1083/jcb.200504137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Finnberg N, Klein-Szanto AJP, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 2008;118:111–123. doi: 10.1172/JCI29900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Lamhamedi-Cherradi S-E, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003;52:2274–2278. doi: 10.2337/diabetes.52.9.2274. [DOI] [PubMed] [Google Scholar]
  • 73.Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 2005;280:15709–15718. doi: 10.1074/jbc.M414469200. [DOI] [PubMed] [Google Scholar]
  • 74.Lamhamedi-Cherradi S-E, Zheng S-J, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 2003;4:255–260. doi: 10.1038/ni894. [DOI] [PubMed] [Google Scholar]
  • 75.Ren X, et al. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 2007;14:2076–2084. doi: 10.1038/sj.cdd.4402220. [DOI] [PubMed] [Google Scholar]
  • 76.Lehnert C, et al. TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation. J. Immunol. 2014;193:4021–4031. doi: 10.4049/jimmunol.1303242. [DOI] [PubMed] [Google Scholar]
  • 77.Ganten TM, et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J. Mol. Med. 2009;87:995–1007. doi: 10.1007/s00109-009-0510-z. [DOI] [PubMed] [Google Scholar]
  • 78.Macher-Goeppinger S, et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 2009;15:650–659. doi: 10.1158/1078-0432.CCR-08-0284. [DOI] [PubMed] [Google Scholar]
  • 79.Heilmann T, et al. Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J. Mol. Med. 2019;97:1155–1167. doi: 10.1007/s00109-019-01805-w. [DOI] [PubMed] [Google Scholar]

Articles from Cell Death Discovery are provided here courtesy of Nature Publishing Group

RESOURCES